Canadian Medical Device Regulation Compared with Twelve Other Markets

1. Key takeaways

The differences between the Canadian medical device regime and other markets concentrate in four points: the classification system (Canada uses Class I / II / III / IV), the role of the local party (in Canada the importer / distributor holds the MDEL, while the product licence, the MDL, is held by the manufacturer itself), the form of the licences (a dual-licence system: the product MDL plus the establishment MDEL, both requiring annual maintenance), and the form of the quality management system evidence (the MDSAP certificate, mandatory as a practical estimate from 2019-01-01).

• Canada uses Class I / II / III / IV; the four-level naming has a different meaning in each market and the numbers do not map one to one.
• In Canada the importer or distributor holds the MDEL and the manufacturer holds the MDL — a structure similar to the United States, not to markets that require a local licence holder.
• The dual-licence system means both the product licence and the establishment licence need annual maintenance (ALR before 1 April; right to sell fee 460 CAD).
• Canadian quality system evidence is the MDSAP certificate (practical estimate: mandatory from 2019-01-01); the United States uses the QMSR.
• Vigilance timelines differ most across markets: days versus hours, and calendar days versus working days, are not interchangeable.
• The twelve-market table below is compiled as a practical estimate for markets other than Canada; the local regulations of each market prevail.

2. Legal basis

The Canadian entries in this comparison are anchored in the Regulations and Health Canada pages; the entries for other markets are practical estimate compilations and each market’s local regulations prevail. The table below lists the sources relied on for the Canadian content.

Twelve-market comparison table (other than Canada, compiled as a practical estimate; the local regulations of each market prevail)

3. Expert insights

The value of a multi-market comparison lies less in the table itself than in knowing which cells must never be filled in by analogy. The insights below highlight the four cells where companies most often go wrong.

Insight 1: Canada uses the structure of a manufacturer-held product licence plus an importer-held establishment licence.

Similar to the United States (where the 510(k) holder is the manufacturer itself and the US Agent is not the licence holder), in Canada the manufacturer holds the MDL. This differs from markets that require the licence to be held by a local licence holder. For companies, this means the concern about “the licence being taken away by an agent” does not arise in Canada.

Insight 2: the naming and numbering of 4-level classification systems carries a different meaning in each market.

Canada’s Class I to IV, Thailand’s Class 1 to 4, the United States’ Class I to III, and Sri Lanka’s Class I to III for general devices and A to D for IVDs do not map one to one onto each other. When filing in multiple markets in parallel, a separate mapping table must be built for each market rather than reusing one conversion.

Insight 3: vigilance timelines show the widest divergence in terminology.

Canada uses “days” (10 days / 30 days) and “hours” (24 hours); the United States uses both calendar days and working days; Thailand uses natural days; Singapore uses calendar days; Bangladesh uses working days. A deadline stated as 10 days can mean three different real lengths depending on whether it counts natural days, calendar days or working days, so the basis must be written out explicitly in every plan.

Insight 4: the form of quality management system evidence is another dividing line between Canada and the United States.

Canada requires the MDSAP certificate (practical estimate: mandatory from 2019-01-01); the United States uses the QMSR (21 CFR 820, effective from 2026-02-02, incorporating ISO 13485:2016 by reference). Both rest on ISO 13485:2016, but the evidence forms differ: the former is a third-party audit certificate, the latter is the system requirement itself.

4. Practical recommendations

• Build a five-column table of “classification — local party — licence — system evidence — vigilance timeline” separately for each market; do not merge them.
• Calculate vigilance timelines separately as natural days, calendar days and working days, and present them side by side.
• Prepare Canadian deliverables according to the dual-licence system: the MDL (product) plus the MDEL (establishment).
• Prepare system evidence separately by market: MDSAP for Canada, QMSR for the United States, ISO 13485 for other markets.
• Annotate every comparison table with the note that entries other than Canada are practical estimate compilations and each market’s local regulations prevail.

5. Verification checklist

• □ A five-column comparison table has been built for each market
• □ Vigilance timelines have been calculated separately as natural days, calendar days and working days
• □ Canadian deliverables have been prepared according to the dual-licence system
• □ System evidence has been prepared separately by market
• □ The comparison tables have been annotated with the practical estimate status and the primacy of local regulations
• □ The cross-market role-name comparison table has been incorporated into training

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Canadian market. Our team manages Health Canada Medical Device Licence and MDEL applications, prepares risk-classified dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com